The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: a sub-analysis of BIOSTAT-CHF

Antoni Bayes-Genis MD, PhD (1)*, Júlio Núñez MD, PhD (2)*, Faiez Zannad MD, PhD (3), João Pedro Ferreira MD, PhD (3,4), Stefan Anker D MD, PhD (5), John G Cleland MD (6), Kenneth Dickstein MD (7), Gerasimos Filippatos MD (8), Chim C Lang MD (9), Leong L Ng MD (10), Piotr Ponikowski MD (11), Nilesh J Samani MD (10), Dirk J van Veldhuisen MD (12), Aeilko H Zwinderman MD (13), Marco Metra MD (14), Josep Lupón MD, PhD (1), Adriaan A Voors MD (13).

From: (1) Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, and Department of Medicine, CIBERCV, Autonomous University of Barcelona, Barcelona, Spain; (2) Cardiology Department. Hospital Clínico Universitario, INCLIVA. Departamento de Medicina. Universitat de València. València, Spain; CIBERCV; (3) Inserm, Centre d'Investigation Clinique Plurithématique 1433, Inserm U1116, Université de Lorraine, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France; (4) Department of Physiology and Cardiothoracic Surgery, Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal; (5) Division of Cardiology and Metabolism – Heart Failure, Cachexia & Sarcopenia; Department of Cardiology (CVK); and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), at Charité University Medicine, Berlin, Germany. Department of Cardiology and Pneumology, University Medicine Göttingen (UMG), Göttingen, Germany & DZHK (German Center for Cardiovascular Research); (6) National Heart & Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College, London, United Kingdom; (7) University of Bergen, Stavanger University

Hospital, Stavanger, Norway; (8) National and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Heart Failure Unit, Athens University Hospital Attikon, Athens, Greece; (9) School of Medicine Centre for Cardiovascular and Lung Biology, Division of Medical Sciences, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK; (10) Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK and NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, LE3 9QP, UK; (11) Department of Heart Diseases, Wroclaw Medical University, Poland and Cardiology Department, Military Hospital, Wroclaw, Poland; (12) Department of Cardiology, University of Groningen, Groningen, the Netherlands; (13) Department of Epidemiology, biostatistics & bioinformatics, Academic Medical Center, Amsterdam, The Netherlands; (14) Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, university of Brescia Italy.

*Both authors contributed similarly in the present study

Short Title: PCSK9 and LDLR in heart failure

Word Count: 4859

Funding: This project was funded by a grant from the European Commission (FP7-242209-BIOSTAT-CHF; EudraCT 2010–020808–29). AB-G was supported by grants from the Ministerio de Educación y Ciencia (SAF2014-59892), Fundació La MARATÓ de TV3 (201502, 201516), CIBER Cardiovascular (CB16/11/00403), and AdvanceCat 2014-2020.

Conflicts of interest: AB-G received board membership fees and travel expenses from Novartis, Roche Diagnostics, and Critical Diagnostics. JN Received board membership fees and travel expenses from Novartis, Roche Diagnostics, Abbott, Rovi and Vifor. AAV received consultancy fees and/or research grants from: Alere, Amgen, Bayer, Boehringer Ingelheim, Cardio3Biosciences, Celladon, GSK, Merck/MSD, Novartis, Servier, Stealth Peptides, Singulex, Sphingotec, Trevena, Vifor, and ZS Pharma. SDA received grants from Vifor and Abbott Vascular and fees for consultancy or speaking from Vifor, Bayer, Boehringer Ingelheim, Brahms, Janssen, Novartis, Servier, and Stealth Peptides, and ASTRA. GF has received committee fees and/or research grants from Novartis, Bayer, Vifor, Servier. PvdH received a research grant from Abbott. CL received consultancy fees and/or research grants from Amgen, Astra Zeneca, MSD, Novartis, and Servier. DVV received board membership fees or travel expenses from Novartis, Johnson & Johnson, and Vifor. MM has received consulting honoraria from Amgen, Astra-Zeneca, Bayer, Novartis, Relypsa, Servier, Stealth therapeutics, and Trevena and speaker's fees from Abbott Vascular and Servier All other authors declare no conflict of interest.

Corresponding Author:

- Antoni Bayes-Genis, MD, PhD, FESC. Head, Heart Institute. Hospital Universitari Germans Trias i Pujol. Carretera de Canyet s/n 08916. Badalona (Barcelona), Spain. E-mail: abayesgenis@gmail.com.

ABSTRACT

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds low-density lipoprotein receptor (LDLR) preventing its recycling. PCSK9 is a risk predictor and a biotarget in atherosclerosis progression.

Objectives: We determined whether the PCSK9-LDLR axis could predict risk in patients with heart failure (HF).

Patients and Methods: The BIOSTAT-CHF is a multicenter, multinational, prospective, observational study that included patients with worsening HF signs and/or symptoms. The primary endpoints were all-cause mortality and the composite of mortality or unscheduled hospitalizations for HF. We implemented Cox proportional hazard regression to determine the simultaneously-adjusted effect of PCSK9 and LDLR on both outcomes, when added to the previously validated BIOSTAT risk scores.

Results: This study included 2174 patients (mean age 68 ± 12 years; 53.2% had a history of ischemic heart disease). Median (IQR) PCSK9 and LDLR levels were 1.81U/mL (1.45-2.18) and 2.98 U/mL (2.45-3.53), respectively. During follow-up, 569 deaths (26.2%) and 896 (41.2%) composite endpoints were ascertained. A multivariable analysis, which included BIOSTAT risk scores, LDLR, and statin treatment as covariates, revealed a positive linear association between PCSK9 levels and the risk of mortality (HR=1.24; 95%CI 1.04-1.49; p=0.020) and the composite endpoint (HR=1.21; 95%CI 1.05-1.40; p=0.010). A similar analysis for LDLR revealed a negative association with mortality (HR=0.86; 95%CI 0.76-0.98; p=0.025) and the composite endpoint (HR=0.92; 95%CI 0.83-1.01; p=0.087). Including PCSK9 and LDLR improved risk score performance.

Conclusions: The PCSK9-LDLR axis was associated with outcomes in patients with HF. Future studies must assess whether PCSK9 inhibition will result in better outcomes in HF.

Keywords: Proprotein convertase subtilisin/kexin type 9 (PCSK9), low-density lipoprotein receptor (LDLR), heart failure.

CONDENSED ABSTRACT

Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds low-density lipoprotein receptor (LDLR) preventing its recycling. We determined whether the PCSK9-LDLR axis could predict risk in patients with heart failure (HF) in the BIOSTAT-CHF study. A multivariable analysis, which included BIOSTAT risk scores, LDLR, and statin treatment as covariates, revealed a positive linear association between PCSK9 levels and the risk of mortality and the composite endpoint. A similar analysis for LDLR revealed a negative association with mortality and the composite endpoint. Future studies must assess whether PCSK9 inhibition will result in better outcomes in HF.

ABBREVIATIONS

HF - Heart failure

PCSK-9- Proprotein convertase subtilisin/kexin type 9

LDLR- low-density lipoprotein receptor

BIOSTAT-CHF- BIOlogy Study to TAilored Treatment in Chronic Heart Failure

LVEF- Left ventricular ejection fraction

ACE- Angiotensin-converting enzyme

PEA- Proximity Extension Assay technology

INTRODUCTION

Major advances in heart failure (HF) management have been achieved over the last three decades by targeting two main pathways activated in HF, namely the renin-angiotensin-aldosterone system and the sympathetic nervous system (1-5). Nevertheless, HF remains a syndrome with high morbidity and mortality, poor quality of life, and high health-care costs (6).

Targeting alternative pathways that participate in the HF syndrome seem the next logical approach. One such pathway is atherosclerosis progression; however, the administration of statins in HF has led to debatable results. Indeed, the two major randomized trials that studied the effect of statin treatment in patients with chronic HF did not demonstrate sufficient evidence of benefit (7,8). However, at least in CORONA the secondary endpoint of heart failure hospitalization was significantly reduced by rosuvastatin (7). Also, some reports on real-life data have shown a positive association between statins and outcomes (9).

A new biotarget for treating atherosclerosis progression is proprotein convertase subtilisin/kexin type 9 (PCSK9)(10,11). Secreted into the plasma by the liver, PCSK9 binds the low-density lipoprotein (LDL) receptor (LDLR) at the surface of hepatocytes. This binding prevents LDLR recycling and enhances its degradation in endosomes and lysosomes, which results in reduced LDL-cholesterol clearance (12). The recent Glavov (13) and Fourier (14) studies have demonstrated that PCSK9 inhibition with monoclonal antibodies could reduce the atherosclerosis disease burden and cardiovascular events.

The potential of PCSK9 as a biotarget in HF is unknown. Herein, we hypothesized that, similar to what was shown in patients with coronary artery disease, elevated levels of PCSK9 in HF are associated with outcomes. Accordingly, we aimed to decipher the value of the PCSK9-LDLR axis for predicting risk in patients with HF in

the multicenter BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) cohort (15).

METHODS

BIOSTAT-CHF Cohort

The BIOSTAT-CHF was a multicenter, multinational, prospective, observational study that included 2516 patients with worsening signs and/or symptoms of HF from 69 centers in 11 European countries. The recruitment period was 24 months, from December 2010 to December 2012 (15). The median follow-up was 21months [interquartile range (IQR) 15–27months]. The Ethics Committees of participating institutions approved this study, and all patients provided written consent to participate in the study.

Eligible patients, exclusion criteria, and characteristics of the BIOSTAT-CHF cohort have been described elsewhere (15). In brief, the majority of patients were hospitalized for acute HF, and the remainder presented with worsening signs and/or symptoms of HF at outpatient clinics. Approximately half of the patients were classified as New York Heart Association class III. Blood was drawn within days of the worsening HF event (either in- or outpatient).

All deaths and hospitalizations were recorded. The primary outcomes of interest were the time to all-cause mortality and the time to a composite of death or unscheduled hospitalization for HF.

PCSK9 and LDL Receptor Assays.

PCSK9 and LDLR were measured using the Proseek® Multiplex CVDIII panel (Olink Proteomics AB, Uppsala, Sweden) according to the manufacturer's instructions. The Proximity Extension Assay (PEA) technology used for the Proseek® Multiplex protocol

has been well described (16). In brief, pairs of oligonucleotide-labeled antibody probes bind to their targeted protein, and if the two probes are brought in close proximity the oligonucleotides will hybridize in a pair-wise manner. The addition of a DNA polymerase leads to a proximity-dependent DNA polymerization event, generating a unique PCR target sequence. The resulting DNA sequence is subsequently detected and quantified using a microfluidic real-time PCR instrument (Biomark HD, Fluidigm). Data is then quality controlled and normalized using an internal extension control and an inter-plate control, to adjust for intra- and inter-run variation. The final assay read-out is presented in Normalized Protein eXpression (NPX) values, which is an arbitrary unit on Log2 scale where a high value corresponds to a higher protein expression. All assay validation data (detection limits, intra- and inter-assay precision data, etc) are available on manufacturer's website (www.olink.com).

Statistical analysis

Continuous variables are expressed as the mean ± standard deviation (SD) or the median (IQR) per variable distribution. Discrete variables are presented as percentages. Baseline characteristics among PSCK9 and LDLR quartiles were compared with ANOVA, Kruskall–Wallis, or chi-squared tests, as appropriate.

The bivariate correlation of the two exposures was assessed with Spearman's rank correlation coefficient. A multivariable linear regression analysis was performed to determine the association of LDLR with PCSK9 while adjusting for age, gender, ischemic heart disease, LDL-cholesterol, HDL-cholesterol, and eGFR.

The Cox proportional hazard regression was used to determine the simultaneously-adjusted effect of PCSK9 and LDLR on all-cause mortality and on the composite of mortality and HF hospitalization. Each of these models included as covariates the use of statins and tertiles of the previously derived BIOSTAT risk score

(17). Briefly, the BIOSTAT risk score for each endpoint was calculated as the probability of achieving the endpoint at a 2-year follow-up. The BIOSTAT risk score for mortality included age, blood urea nitrogen, NT-proBNP, serum hemoglobin, and the use of a beta-blocker. The BIOSTAT risk score for the composite endpoint included age, previous HF-related hospitalization, the presence of edema, systolic blood pressure, and the estimated glomerular filtration rate (17). Results are expressed as hazard ratios (HR) with their respective 95% CI. The proportionality assumption – tested by means of the Schoenfeld residuals - was met for all models. In a sensitivity analysis, LDL cholesterol was added as an additional covariate to the previous prognostic models.

Measures of performance were assessed by means of Δ C-statistics, integrated discrimination improvement (IDI), and net reclassification improvement (NRI)(%). In order to match the scope of the BIOSTAT risk score, these indices were calculated at a horizon of 2 years. Two variations of the analysis are presented: 1) PCSK9, LDLR, and the use of statins are compared over the BIOSTAT risk score alone, and 2) PCSK9 is contrasted against LDLR, use of statins, and the BIOSTAT risk score.

We set a two-sided p-value of <0.05 as the threshold for statistical significance. Stata 14.2 (Stata Statistical Software, Release 14 [2015]; StataCorp LP, College Station, TX, USA), was used for the main analysis. Risk reclassification analyses were implemented in R (Version 3.40; R Foundation for Statistical Computing, Vienna, Austria) with the survIDINRI and SurvC1 modules.

RESULTS

A total of 2174 patients were included in this analysis (Online Figure 1). The mean age of the sample was 68 ± 12 years; 581 (49.7%) were female, 1156 (53.2%) had history of ischemic heart disease, and 1727 (88.8%) exhibited LVEF ≤40% (4.5% had LVEF in

the mid-range and 6.7% had preserved LVEF). The median (IQR) values of PCSK9, LDLR, and NT-proBNP were 1.81U/mL (1.45-2.18), 2.98 U/mL (2.45-3.53), and 4148 pg/mL (2330-8136), respectively. The baseline values of PCSK9 and LDLR across quartiles are shown in Tables 1 and 2. Overall, patients in the higher PCSK9 quartiles displayed a higher prevalence of ischemic heart disease and prior coronary revascularization and higher values of creatinine, and potassium (Table 1). In contrast, the disease severity surrogates were inversely related to the LDLR quartiles. Indeed, those in the lower LDLR quartiles were older, more frequently males, and exhibited higher proportions of prior renal failure and atrial fibrillation. Similarly, the lower LDLR quartile displayed lower systolic blood pressure and hemoglobin, and higher values of urea and NT-proBNP (Table 2). Regarding medications, higher proportions of patients used statins in the upper quartiles of the two studied exposures. (Tables 1, 2). LVEF categories, as defined in the ESC Guidelines (1), were similarly distributed across PCSK9 and LDLR quartiles (p=0.365 and p=0.193, respectively).

Circulating PCSK9 predictors

Online Figure 2 shows the identified predictors of circulating PCSK9 levels. The model's adjusted R-squared was 0.422. A closer look at the positive correlation between PCSK9 and LDLR is depicted in Online Figure 3 ($r = 0.59$; $p<0.001$). Exploratory analyses across NT-proBNP quartiles with PCSK9 and LDLR did not show prognostic differences on all-cause mortality or the composite endpoint.

Mortality endpoint

During a median follow-up of 1.78 years (IQR: 1.29-2.25), 569 deaths (26.2%) were registered. Multivariable analysis that included as covariates the BIOSTAT risk score for mortality, LDLR, and statin treatment, revealed a positive linear association between PCSK9 and the risk of mortality (p=0.020; Figure 1A). A similar analysis revealed a

negative linear association between LDLR and mortality (p=0.025; Figure 1B). The estimated HRs from regression modeling are shown in Table 3. Since PCSK9 and LDLR levels were highly correlated, we excluded one exposure at a time to assess -on the other one- if multicollinearity was artificially changing in the direction of the effect. Under this premise, a positive association for all-cause mortality was confirmed for PCSK9 and a negative one for LDLR (results not shown). Indeed, both variables' linear trajectories showed opposite directions, with increasing risk at higher PCSK9 levels and lower risk at higher LDLR levels (Figure 1).

In exploratory fashion, several interactions were tested, all with negative results: PCSK9 quartiles vs LDLR (p = 0.388); LDLR quartiles vs PCSK9 (p = 0.143); statins vs PCSK9 (p = 0.432); statins vs LDLR (p = 0.860); ischemic heart disease vs PCSK9 (p = 0.271); and ischemic heart disease vs LDLR (p = 0.079).

The added value in performance for PCSK9, LDLR, and statin treatment over the BIOSTAT risk score was confirmed by Δ C-statistic [0.0120 (0.002-0.022); p=0.019], IDI [0.3 (0-1.1)], and NRI [6.0 (0-11.9)]. Similarly, PCSK9 produced a better risk reclassification over LDLR, statin treatment, and the BIOSTAT risk score as evidenced by IDI [0.6 (0.1-1.8)] and NRI [11.0 (1.0-18.3)].

Composite endpoint

At a median follow-up of 1.53 years (IQR, 0.67-2.15), we ascertained 896 (41.2%) composite endpoints (composite of death or HF-related hospitalization). In a multivariable context, PCSK9 showed a linear and positive association with the risk of the combined endpoint (p=0.011; Figure 2A), independent of the effect of BIOSTAT risk score for the composite endpoint, LDLR, and statin treatment; LDLR, however, showed a negative but borderline association (p=0.087; Figure 2B). The estimated HRs from regression modeling are shown in Table 3. The direction of the effect for both

PCSK9 and LDLR were confirmed by excluding one of them at a time to rule-out changes due to multicollinearity.

In exploratory fashion, several interactions were tested, all with negative results: PCSK9 quartiles vs LDLR (p = 0.200); LDLR quartiles vs PCSK9 (p = 0.929); statins vs PCSK9 (p = 0.485); statins vs LDLR (p = 0.403); ischemic heart disease vs PCSK9 (p = 0.170); and ischemic heart disease vs LDLR (p = 0.211).

The added value in performance for PCSK9, LDLR, and statin treatment over the BIOSTAT risk score was confirmed by Δ C-statistic [0.014 (0.006-0.022): p<0.001], IDI [0.8 (0.2-1.8)], and NRI [10.8 (2.9-15.0)]. Similarly, PCSK9 produced a better risk reclassification over LDLR, statin treatment, and the BIOSTAT risk score both by IDI [0.6 (0-1.5)], and NRI [9.8 (0.4-17.7)].

Sensitivity analysis

In a sensitivity analysis, where plasma LDL cholesterol was added as an additional covariate, the results were consistent with the main findings, despite a drop in sample numbers (n=1000), due to missing LDL cholesterol values. Circulating PCSK9 and LDLR levels were independently associated with mortality risk and the composite endpoint (Online Table 1).

DISCUSSION

The present report is the first to show that the PCSK9-LDLR axis was associated with poor outcomes in patients with HF. Our sub-analysis of the BIOSTAT-CHF cohort indicated that soluble PCSK9 was positively associated with both all-cause mortality and the composite endpoint of mortality or HF-related rehospitalizations in patients with worsening HF. By contrast, as pathobiologically expected, circulating LDLR was

inversely associated with the same two endpoints. Interestingly, the predictive value of PCSK9 improved after adjusting for traditional prognosticators and soluble LDLR.

The predictive value of circulating PCSK9 concentrations was previously described in other clinical settings of cardiovascular pathology (19-20). In the context of HF, a comprehensive multivariable analysis with validated BIOSTAT risk scores showed that higher PCSK9 was associated with an increased incidence of the composite endpoint, and this relationship was independent of serum LDL cholesterol, statin use, or ischemic HF etiology. Thus, PCSK9 may be considered a risk predictor across the cardiovascular disease continuum, from asymptomatic dyslipidemia, through sub-clinical and clinical atherosclerosis, and in HF, based on our findings (Central Illustration).

Secreted PCSK9 follows two possible tracks: the first is to bind immediately to LDLRs in the liver, and the second is to enter the systemic circulation (12). Once bound, the PCSK9/LDLR complex is endocytosed, taken into the lysosomes, and undergoes degradation (21). The presence of PCSK9 enhances LDLR degradation; therefore this track reduces the LDLR abundance on the cell surface (22). In the plasma, circulating PCSK9 can bind to LDLRs on the membranes of various organ systems, such as the liver, intestines, kidneys, lungs, pancreas, and adipose tissues (23-27). In the present report, although the ability for risk prediction of PCSK9 and LDLR was opposite when included in comprehensive multivariable models, their circulating concentrations showed a significant positive correlation. This finding may reflect the already recognized complexity of the PCSK9-LDLR axis (28). Indeed, Tavori et al report that in addition to the straightforward mechanism of action (PCSK9 terminating the lifecycle of LDLR), there are more complex interactions between PCSK9, LDLR and plasma lipoprotein levels, including: (a) the presence of both parallel and reciprocal

regulation of surface LDLR and plasma PCSK9; (b) a correlation between PCSK9 and LDL cholesterol levels dependent not only on the fact that PCSK9 removes hepatic LDLR, but also due to the fact that up to 40% of plasma PCSK9 is physically associated with LDL; and (c) an association between plasma PCSK9 production and the assembly and secretion of triglyceride-rich lipoproteins (28).

Despite numerous advances in HF treatments, which block both the sympathetic nervous system and the renin-angiotensin-aldosterone system, the morbidity and mortality of patients with HF remain unacceptably high (29). Our finding that PCSK9 could predict risk in HF may serve as a basis for designing prospective studies that aim to inhibit PCSK9, either with specific PCSK9 neutralizing monoclonal antibodies or with the administration of small, interfering RNAs (siRNAs) that specifically bind and inhibit translation of PCSK9 mRNAs (13,14,30).

In patients with acute coronary syndromes, the potential benefit of treatment with PCSK9 antibodies may be two-fold, because it could both reduce LDL cholesterol and stabilize plaques (10). Indeed, PCSK9 adversely affects coronary plaques through several pathways, including proinflammatory LDL oxidation and direct modification of plaque composition. Moreover, PCSK9 is associated with the inflammatory response, which is largely based on NF-κB–mediated expression of proinflammatory genes, including cytokines, chemokines, and adhesion molecules (31,32). The PCSK9-induced NF-κB pathway can upregulate tissue factor expression, which enhances the thrombotic substrate in atherosclerotic plaques (33). In the context of HF, it is reasonable to speculate that plaque stabilization, combined with reductions in the prothrombotic and proinflammatory states, accomplished by inhibiting PCSK9, might represent a new avenue of treatment for preventing disease progression, when the current optimal medical treatment is insufficient. It is unclear whether this strategy will be useful across

all HF etiologies, or only for those of ischemic origin; this issue should be investigated in future, well-designed, prospective clinical trials.

Two randomized clinical trials that explored reducing cholesterol levels with rosuvastatin in patients with HF did not demonstrate a clear benefit (7,8). Rosuvastatin is a hydrophilic statin, which relies on active transport into hepatocytes to exert its effect and has poor penetration into extrahepatic tissues; thus, it has less risk of adverse effects but also very low uptake by cardiac muscle. No randomized studies have been performed with lipophilic statins (simvastatin, atorvastatin), which tend to achieve higher levels of exposure in nonhepatic tissues, have very high cardiac muscle uptake, and in real-life scenarios have shown some benefit (9,34). Current guidelines do not recommend the use of statins in patients with HF (1). Whether interfering with cholesterol-related mechanistic pathway may be beneficial in selected patients with HF is not a totally settled issue (35).

Limitations: The current study had some limitations. First, the data presented here are valid for patients with worsening HF, mainly due to reduced LVEF. It remains to be determined whether soluble PCSK9 is also a good predictor for patients with stable chronic HF. Currently available data in the context of coronary artery disease showed in mice that plasma PCSK9 concentration was mostly elevated in the early hours after an acute coronary syndrome (36). The second limitation was that the assay used to measure PCSK9 and LDLR was designed for research only, and its use cannot be recommended in clinical practice. Nevertheless, both exposures were measured with state-of-the art proteomics technology, currently available and well validated (16). The last limitation was that genetic mutations that might determine PCSK9 levels were not measured in patients enrolled in the BIOSTAT-CHF trial. PCSK9 gain-of-function mutations have been associated with increased severity in coronary atherosclerosis (37).

CONCLUSION

The PCSK9-LDLR axis has been investigated expeditiously, from discovery to targeted therapy, in dyslipidemia and coronary atherosclerosis. Here, we provided the first evidence of PCSK9 participation in HF. Indeed, HF risk was positively associated with circulating PCSK9 and negatively associated with LDLR in patients with worsening HF. Future studies are needed to better understand the PCSK9-LDLR axis in HF, and to assess whether PCSK9 inhibition or silencing might lead to better outcomes in HF.

PERSPECTIVES

Competency in Medical Knowledge: Proprotein convertase subtilisin/kexin type 9 (PCSK9), which binds the low-density lipoprotein receptor (LDLR) and prevents its recycling, is a risk predictor and biotarget in atherosclerosis progression. Here, we demonstrated that HF risk was positively associated with circulating PCSK9 and negatively associated with LDLR levels.

Translational Outlook: Our data provided a basis for future research to investigate whether HF outcomes might be improved by inhibiting PCSK9, either with specific PCSK9-neutralizing monoclonal antibodies or with small interfering RNAs (siRNAs).

REFERENCES

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200.
2. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273:1450–6.
3. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349–1355.
4. Zannad F, McMurray JJV, Krum H, Van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21.
5. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.
6. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L,

Crespo Leiro M, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2013;15:808–817

7. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJV, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248–2261.
8. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-9.
9. Gastelurrutia P, Lupón J, de Antonio M, Urrutia A, Díez C, Coll R, Altimir S, Bayes-Genis A. Statins in heart failure: the paradox between large randomized clinical trials and real life. Mayo Clin Proc. 2012 Jun;87(6):555-60.
10. Navarese EP, Kolodziejczak M, Kereiakes DJ, Tantry US, O'Connor C, Gurbel PA. Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review. Ann Intern Med. 2016 May 3;164(9):600-7.
11. Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014 Mar 14;114(6):1022-36.

12. Shimada YJ, Cannon CP.PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Eur Heart J. 2015 ;36:2415-24.

13. Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA 2016;316:2373-2384.

14. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017;376:1713-1722.

15. Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Ter Maaten JM, Ng L, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Metra M. A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. Eur J Heart Fail 2016;18:716-26.

16. Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Bucht Thorsen S, Ekman D, Eriksson A, Rennel Dickens E, Ohlsson S, Edfeldt G,Andersson AC, Lindstedt P, Stenvang J, Gullberg M, Fredriksson S. Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, specificity, and Excellent Scalability. *PLoS One* April (2014). doi: 10.1371/journal.pone.0095192.

17. Voors AA, Ouwerkerk W, Zannad F, van Veldhuisen DJ, Samani NJ, Ponikowski P, Ng LL, Metra M, Ter Maaten JM, Lang CC, Hillege HL, van der Harst P, Filippatos G, Dickstein K, Cleland JG, Anker SD, Zwinderman AH.

Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. Eur J Heart Fail. 2017;19:627-34.

18. Royston P and Sauerbrei W. Multivariable Model-building: A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Modelling Continuous Variables. Chichester, UK: Wiley, 2008.

19. Almontashiri NA, Vilmundarson RO, Ghasemzadeh N, Dandona S, Roberts R, Quyyumi AA, et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS One. 2014;9:e106294.

20. Cheng J, Oemrawsingh R, Garcia-Garcia H, Boersma E, Van Geuns R, Serruys P, et al. PCSK9 in relation to coronary plaque inflammation and cardiovascular outcome. In: Cheng JM, Boersma H. Coronary Artery Disease: From Atherosclerosis to Cardiogenic Shock. Rotterdam, the Netherlands: Erasmus University Rotterdam; 2015:221-38.

21. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growthfactor-likerepeatAoflowdensitylipoproteinreceptordecreasesreceptor recycling and increases degradation. J Biol Chem 2007;282:18602–18612.

22. Poirier S, Mayer G, Benjanne S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah G.The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 2008;283:2363–2372.

23. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD. Secreted PCSK9 decreases the number of

LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006;116: 2995–3005.

24. Schmidt RJ, Beyer TP, Bensch WR, Qian YW, Lin A, Kowala M, Alborn WE, Konrad RJ, Cao G. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem Biophys Res Commun 2008;370:634–640.

25. Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. ProcNatlAcad Sci USA 2005;102:2069–2074.

26. Tavori H, Rashid S,Fazio S.On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis 2014;238: 264–270.

27. Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Ter Maaten JM, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Metra M, Zwinderman AH. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017 Mar 11. doi: 10.1093/eurheartj/ehx026. [Epub ahead of print].

28. Tavori H, Rashid S, Fazio S. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis 2015;238:264-70.

29. Dunlay SM, Redfield MM, Weston SA, Therneau TM, Hall Long K, Shah ND, Roger VL. Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol 2009;54:1695–1702.

30. Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troquay RP, Turner T, Visseren FL, Wijngaard P, Wright RS, Kastelein JJ. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med 2017;376:1430-1440.

31. Ding Z, Liu S, Wang X, Deng X, Fan Y, Shahanawaz J, et al. Cross-talkbetweenLOX-1andPCSK9invasculartissues.Cardiovasc Res. 2015;107:556-67.

32. Tang Z, Jiang L, Peng J, Ren Z, Wei D, Wu C, et al. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappa B activation in THP-1-derived macrophages. Int J MolMed.2012;30:931-8.

33. Orthner CL, Rodgers GM, Fitzgerald LA. Pyrrolidine dithiocarbamate abrogates tissue factor (TF) expression by endothelial cells: evidence implicating nuclear factorB in TF induction by diverse agonists. Blood 1995;86:436-43.

34. Bonsu KO, Reidpath DD, Kadirvelu A. Lipophilic Statin Versus Rosuvastatin (Hydrophilic) Treatment for Heart Failure: a Meta-Analysis and Adjusted Indirect Comparison of Randomised Trials. Cardiovasc Drugs Ther 2016;30:177-88.

35. Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R, Coats AJ, Anker SD. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933-40.

36. Zhang Y, Liu J, Li S, Xu RX, Sun J, Tang Y, et al. Proprotein convertase subtilisin/kexin type 9 expression is transiently upregulated in the acute period of myocardial infarction in rat. BMC Cardiovasc Disord. 2014;14:192.

37. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat

A, Krempf M, Junien C, Seidah NG,Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154–156.

FIGURE LEGENDS

Figure 1: Multivariable analyses for all-cause mortality. (A) HR-gradient, with the median PCSK9 value (1.81 U/mL) as reference. Analysis adjusted for LDLR, statins, and the BIOSTAT risk score for mortality. (B) HR-gradient, with the median LDLR value (2.98 U/mL) as reference. Analysis adjusted for PCSK9, statins, and the BIOSTAT risk score for mortality. HR, hazard ratio; PCSK9, proprotein convertase subtilisin/kexin type 9; LDLR, low density lipoprotein- receptor. U/mL, is a Normalized Protein eXpression (NPX) arbitrary unit (see Methods for details).

Figure 2: Multivariable analyses for the composite endpoint (mortality or HF-related hospitalization). (A) HR-gradient, with the median PCSK9 value (1.81 U/mL) as reference. Analysis adjusted for LDLR, statins, and the BIOSTAT risk score for the composite endpoint. (B) HR-gradient, with the median LDLR value (2.98 U/mL) as reference. Analysis adjusted for PCSK9, statins, and the BIOSTAT risk score for the composite endpoint. HR, hazard ratio; PCSK9, proprotein convertase subtilisin/kexin type 9; LDLR, low density lipoprotein-receptor. U/mL, is a Normalized Protein eXpression (NPX) arbitrary unit (see Methods for details).

Central Illustration: PCSK9 across the cardiovascular continuum. In heart failure we proved evidence of elevated PCSK9 levels, which were associated with poor outcomes. There is no evidence of PCSK9 inhibition in HF.

Table 1: Demographic, clinical, laboratory and treatment characteristics relative to PCSK9 quartiles

Variables	PCSK9				P value
	1st Quartile N= 544	**2nd Quartile** N=543	**3rd Quartile** N=544	**4th Quartile** N=543	
Age, years, mean (sd)	69 (12)	69 (13)	67 (12)	68 (12)	0.08
Sex, male, n (%)	413 (75.9)	401 (73.8)	391 (71.9)	388 (71.5)	0.32
Ischemic heart disease, n (%)	273 (50.7)	273 (51.3)	277 (52.7)	333 (61.8)	0.001
Dilated cardiomypathy, n (%)	167 (30.7)	186 (34.3)	157 (28.9)	156 (28.7)	0.17
Hypertension, n (%)	347 (63.8)	322 (59.3)	323 (59.4)	355 (65.4)	0.09
Diabetes mellitus, n (%)	173 (31.8)	172 (31.7)	171 (31.4)	185 (34.1)	0.77
Renal failure, n (%)	162 (29.8)	153 (28.2)	131 (24.1)	169 (31.1)	0.06
Atrial fibrillation, n (%)	243 (44.7)	266 (49.0)	254 (46.7)	228 (42.0)	0.12
Heart rate (bpm), mean (SD)	81 (19)	80 (20)	79 (20)	80 (19)	0.67
LVEF %, mean (SD)*	32 (11)	30 (10)	31 (10)	31 (11)	0.28
Laboratory					
Hemoglobin (g/dL), mean (SD)	13.0 (1.9)	13.1 (1.8)	13.2 (1.9)	13.4 (2.0)	0.07
Serum creatinine, mg/dl, mean (SD)	1.28 (0.52)	1.27 (0.53)	1.27 (0.67)	1.38 (0.74)	0.008
NT-proBNP (ng/L), median (IQR)	3975 (2288; 7751)	4654 (2364; 8475)	3784 (2242; 8105)	3949 (2360; 8000)	0.61
LDLc (mmol/L), mean (SD) ¶	2.54 (0.99)	2.50 (0.98)	2.65 (1.11)	2.67 (1.14)	0.21

Treatment					
Diuretics, n (%)	543 (99.8)	543 (100.0)	544 (100.0)	542 (99.8)	0.57
MRA, n (%)	270 (49.6)	290 (53.4)	300 (55.1)	282 (51.9)	0.31
Betablocker, n (%)	454 (83.5)	451 (83.1)	443 (81.4)	459 (84.5)	0.59
ACEI/ARB, n (%)	390 (71.7)	387 (71.3)	383 (70.4)	399 (73.5)	0.72
Statins, n (%)	257 (47.3)	251 (46.1)	301 (55.3)	340 (62.2)	<0.001

PCSK9, proprotein convertase subtilisin/kexin type 9; LDLR, low density lipoprotein receptor; LDLc, LDL cholesterol; NTpro-BNP, N-terminus pro B-type natriuretic peptide; MRA, mineralo-receptor antagonists; ACEI, angiotensin coverting-enzyme inhibitors; ARB, angiotensin receptor 2 inhibitors; SD, standard deviation; IQR, interquartile range; bpm, beats per minute. U/mL, is a Normalized Protein eXpression (NPX) arbitrary unit (see Methods forr details). [*]data available in 1946 patients; [¶]data available in 1000 patients.

Table 2: Demographic, clinical, laboratory and treatment characteristics relative to LDLR quartiles

Variables	LDLR				P value
	1st Quartile N= 544	**2nd Quartile** N=543	**3rd Quartile** N=544	**4th Quartile** N=543	
Age, years, mean (sd)	70 (12)	69 (12)	68 (12)	66 (12)	< 0.001
Sex, male, n (%)	425 (78.1)	409 (75.3)	397 (73.0)	362 (66.7)	< 0.001
Ischemic heart disease, n (%)	280 (52.3)	295 (55.5)	288 (54.0)	293 (54.8)	0.76
Dilated cardiomypathy, n (%)	154 (28.3)	161 (29.7)	163 (30.0)	188 (34.6)	0.12
Hypertension, n (%)	349 (64.2)	314 (57.8)	327 (60.1)	357 (65.7)	0.03
Diabetes mellitus, n (%)	167 (30.7)	162 (29.8)	177 (32.5)	195 (35.9)	0.15
Renal failure, n (%)	180 (33.1)	153 (28.2)	136 (25.0)	146 (26.9)	0.02
Atrial fibrillation, n (%)	285 (52.4)	259 (47.7)	250 (46.0)	197 (36.3)	< 0.001
Heart rate (bpm), mean (SD)	80 (19)	80 (20)	81 (21)	80 (19)	0.94
LVEF %, mean (SD)*	31 (11)	30 (11)	31 (11)	31 (10)	0.50
Laboratory					
Hemoglobin (g/dL), mean (SD)	12.8 (1.9)	13.2 (1.9)	13.2 (1.9)	13.5 (1.9)	< 0.001
Serum creatinine, mg/dl, mean (SD)	1.32 (0.59)	1.28 (0.71)	1.31 (0.60)	1.29 (0.58)	0.66
NT-proBNP (ng/L), median (IQR)	4339 (2420; 8068)	5302 (2767; 9449)	3632 (2358; 7340)	3499 (1775; 7337)	< 0.001
Treatment					

Diuretics, n (%)	543 (99.8)	543 (100.0)	544 (100.0)	542 (99.8)	0.57
MRA, n (%)	297 (54.6)	299 (55.1)	277 (50.9)	269 (49.5)	0.18
Betablocker, n (%)	440 (80.9)	462 (85.1)	448 (82.4)	457 (84.2)	0.25
ACEI/ARB, n (%)	396 (72.8)	383 (70.5)	382 (70.2)	398 (73.3)	0.58
Statins, n (%)	268 (49.9)	279 (51.3)	278 (51.1)	324 (59.7)	0.003

LDLR, low density lipoprotein receptor; PCSK9, proprotein convertase subtilisin/kexin type 9; LDLc, LDL cholesterol; NTpro-BNP, N-terminus pro B-type natriuretic peptide; MRA, mineralo-receptor antagonists; ACEI, angiotensin coverting-enzyme inhibitors; ARB, angiotensin receptor 2 inhibitors; SD, standard deviation; IQR, interquartile range; LVEF, left ventricular ejection fraction; bpm, beats per minute. U/mL, is a Normalized Protein eXpression (NPX) arbitrary unit (see Methods for details). [*]data available in 1946 patients; [¶]data available in 1000 patients

Table 3. Regression modeling for all-cause mortality and the composite endpoint of mortality and/or HF-related hospitalization

Endpoint	HR	95% CI	P-value
All-cause mortality			
PCSK9	1.24	1.04 - 1.49	0.020
LDLR	0.86	0.76 - 0.98	0.025
Statins	1.03	0.87 - 1.22	0.725
Risk score[†]			<0.001[*]
Tertile 1	1.00		
Tertile 2	2.35	1.76 - 3.13	0.000
Tertile 3	6.41	4.92 - 8.36	0.000
Mortality/HF-related hospitalization			
PCSK9	1.21	1.05 - 1.40	0.011
LDLR	0.92	0.83 - 1.01	0.087
Statins	1.25	1.09 - 1.42	0.001
Risk score[‡]			<0.001[*]
Tertile 1	1.00		
Tertile 2	2.87	2.32 - 3.56	0.000
Tertile 3	6.13	5.00 - 7.52	0.000

PCSK9, proprotein convertase subtilisin/kexin type 9; LDLR, low density lipoprotein- receptor; HR, hazard ratio; CI, confidence interval.[†]BIOSTAT Score for mortality includes: age, blood urea nitrogen, NT-pro-BNP, serum hemoglobin, and use of beta-blocker; [‡]BIOSTAT Score for mortality/HF-related rehospitalization includes: age, previous HF-related hospitalization, presence of edema, systolic blood pressure, and estimated glomerular filtration rate. [*]Omnibus P value.